$4.42 Billion is the total value of RA Capital Management's 59 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 27.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | ASCENDIS PHARMA A/S | $745,948,732 | -12.2% | 6,957,179 | 0.0% | 16.89% | -2.0% | |
| PCVX | Buy | VAXCYTE INC | $273,276,200 | -2.7% | 7,291,254 | +24.5% | 6.19% | +8.6% |
| Buy | DICE THERAPEUTICS INC | $225,091,934 | +5.3% | 7,856,612 | +14.7% | 5.10% | +17.6% | |
| ETNB | Buy | 89BIO INC | $173,880,118 | +52.5% | 11,416,948 | +27.5% | 3.94% | +70.2% |
| AVTE | AEROVATE THERAPEUTICS INC | $166,684,517 | -31.2% | 8,263,982 | 0.0% | 3.77% | -23.2% | |
| BIIB | BIOGEN INC | $148,159,963 | +0.4% | 532,892 | 0.0% | 3.35% | +12.1% | |
| VRNA | VERONA PHARMA PLC | $126,865,239 | -23.2% | 6,317,990 | 0.0% | 2.87% | -14.2% | |
| CYTEK BIOSCIENCES INCsponsored adr | $122,971,886 | -10.0% | 13,381,054 | 0.0% | 2.78% | +0.5% | ||
| VOR | VOR BIOPHARMA INC | $122,388,974 | -19.1% | 22,748,880 | 0.0% | 2.77% | -9.7% | |
| LEGN | LEGEND BIOTECH CORP | $117,474,673 | -3.4% | 2,436,223 | 0.0% | 2.66% | +7.8% | |
| TYRA BIOSCIENCES INC | $116,289,816 | +111.4% | 7,236,454 | 0.0% | 2.63% | +136.1% | ||
| JANX | JANUX THERAPEUTICS INC | $104,914,792 | -8.1% | 8,670,644 | 0.0% | 2.38% | +2.5% | |
| PEPGEN INC | $99,453,773 | -8.5% | 8,131,952 | 0.0% | 2.25% | +2.1% | ||
| RNA | Buy | AVIDITY BIOSCIENCES INC | $98,500,919 | -18.6% | 6,416,998 | +17.6% | 2.23% | -9.2% |
| RYTM | RHYTHM PHARMACEUTICALS INC | $98,406,635 | -38.7% | 5,516,067 | 0.0% | 2.23% | -31.6% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $94,133,116 | -37.9% | 7,040,622 | 0.0% | 2.13% | -30.7% | |
| BLU | Buy | BELLUS HEALTH INC NEW | $91,033,733 | -11.1% | 12,643,574 | +1.5% | 2.06% | -0.7% |
| CVAC | New | CUREVAC N Vsponsored ads | $85,354,306 | – | 12,245,955 | +100.0% | 1.93% | – |
| IMGN | IMMUNOGEN INC | $83,919,199 | -22.6% | 21,853,958 | 0.0% | 1.90% | -13.6% | |
| WVE | WAVE LIFE SCIENCES LTD | $74,484,699 | -38.1% | 17,202,009 | 0.0% | 1.69% | -31.0% | |
| INBX | INHIBRX INC | $72,722,470 | -23.4% | 3,853,867 | 0.0% | 1.65% | -14.5% | |
| GERN | Buy | GERON CORPads | $68,452,229 | +118.8% | 31,544,806 | +144.0% | 1.55% | +144.1% |
| COGT | COGENT COMMUNICATIONS HLDGS | $64,734,400 | -6.7% | 5,999,481 | 0.0% | 1.46% | +4.1% | |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $62,424,293 | -32.5% | 1,734,972 | -16.4% | 1.41% | -24.7% |
| ACRIVON THERAPEUTICS INC | $61,045,347 | +10.2% | 4,810,508 | 0.0% | 1.38% | +23.0% | ||
| ITOS | ITEOS THERAPEUTICS INCsponsored adr | $60,118,895 | -30.3% | 4,417,259 | 0.0% | 1.36% | -22.2% | |
| NEWAMSTERDAM PHARMA COMPANY | $53,040,000 | +21.7% | 4,000,000 | 0.0% | 1.20% | +35.9% | ||
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $51,082,146 | +98.7% | 2,007,946 | +128.2% | 1.16% | +121.9% |
| RXSIGHT INCordinary shares | $50,920,637 | +31.6% | 3,052,796 | 0.0% | 1.15% | +47.1% | ||
| New | MINERALYS THERAPEUTICS INC | $49,774,934 | – | 3,178,476 | +100.0% | 1.13% | – | |
| PLRX | New | PLIANT THERAPEUTICS INC | $46,869,200 | – | 1,762,000 | +100.0% | 1.06% | – |
| New | ENLIVEN THERAPEUTICS INC | $46,481,984 | – | 2,122,465 | +100.0% | 1.05% | – | |
| GHRS | Buy | GH RESEARCH PLC | $44,593,476 | -6.3% | 5,581,161 | +13.9% | 1.01% | +4.5% |
| ABOS | ACUMEN PHARMACEUTICALS INCsponsored ads | $39,669,338 | -24.8% | 9,770,773 | 0.0% | 0.90% | -16.1% | |
| ELIEM THERAPEUTICS INC | $38,137,462 | -21.0% | 13,150,849 | 0.0% | 0.86% | -11.8% | ||
| AN2 THERAPEUTICS INC | $37,244,613 | +3.6% | 3,773,517 | 0.0% | 0.84% | +15.6% | ||
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $36,192,248 | +12.0% | 4,688,115 | +6.6% | 0.82% | +25.0% |
| ACRS | ACLARIS THERAPEUTICS INC | $35,583,485 | -48.6% | 4,398,453 | 0.0% | 0.81% | -42.6% | |
| ICOSAVAX INC | $34,588,677 | -27.0% | 5,963,565 | 0.0% | 0.78% | -18.4% | ||
| FULC | Buy | FULCRUM THERAPEUTICS INC | $33,087,656 | -52.2% | 11,609,704 | +22.1% | 0.75% | -46.7% |
| HILLEVAX INC | $29,093,114 | -1.2% | 1,760,019 | 0.0% | 0.66% | +10.4% | ||
| NKTX | NKARTA INC | $27,708,208 | -40.7% | 7,805,129 | 0.0% | 0.63% | -33.9% | |
| KNTE | KINNATE BIOPHARMA INC | $26,650,900 | +2.5% | 4,264,144 | 0.0% | 0.60% | +14.2% | |
| NSTG | Buy | NANOSTRING TECHNOLOGIES | $24,327,003 | +2021.1% | 2,457,273 | +1607.6% | 0.55% | +2295.7% |
| SBTX | ARS PHARMACEUTICALS INC | $19,593,004 | -23.7% | 3,009,678 | 0.0% | 0.44% | -14.8% | |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $19,387,306 | -58.8% | 1,131,775 | -53.0% | 0.44% | -54.0% |
| TENAYA THERAPEUTICS INC | $17,292,327 | +41.8% | 6,067,483 | 0.0% | 0.39% | +58.3% | ||
| DSGN | DESIGN THERAPEUTICS INC | $17,144,003 | -43.8% | 2,971,231 | 0.0% | 0.39% | -37.2% | |
| SOLID BIOSCIENCES INC | $16,240,596 | -11.9% | 3,426,286 | 0.0% | 0.37% | -1.6% | ||
| HOWL | Buy | WEREWOLF THERAPEUTICS INC | $15,976,691 | +81.6% | 6,144,881 | +43.2% | 0.36% | +103.4% |
| CELC | CELCUITY INC | $14,350,010 | -26.8% | 1,400,001 | 0.0% | 0.32% | -18.3% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $9,909,288 | -16.0% | 3,370,506 | 0.0% | 0.22% | -6.3% | |
| CNTB | CONNECT BIOPHARMA HLDGS LTD | $6,990,304 | +15.2% | 6,991,003 | 0.0% | 0.16% | +28.5% | |
| BDTX | BLACK DIAMOND THERAPEUTICS I | $4,894,919 | +5.0% | 2,589,904 | 0.0% | 0.11% | +16.8% | |
| AADI BIOSCIENCE INC | $4,273,178 | -43.6% | 590,218 | 0.0% | 0.10% | -37.0% | ||
| STSA | SATSUMA PHARMACEUTICALS INC | $4,131,105 | -22.4% | 5,914,252 | 0.0% | 0.09% | -13.0% | |
| FUSN | FUSION PHARMACEUTICALS INC | $2,488,170 | +19.7% | 659,992 | 0.0% | 0.06% | +33.3% | |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $613,333 | +111.9% | 333,333 | 0.0% | 0.01% | +133.3% | ||
| ENTX | ENTERA BIO LTD | $343,321 | +58.9% | 295,966 | 0.0% | 0.01% | +100.0% | |
| IMUX | Exit | IMMUNIC INC | $0 | – | -632,184 | -100.0% | -0.02% | – |
| ACHL | Exit | ACHILLES THERAPEUTICS PLCsponsored ads | $0 | – | -1,607,834 | -100.0% | -0.03% | – |
| Exit | THIRD HARMONIC BIO INC | $0 | – | -534,687 | -100.0% | -0.05% | – | |
| Exit | IO BIOTECH INC | $0 | – | -1,127,260 | -100.0% | -0.05% | – | |
| DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -1,958,957 | -100.0% | -0.06% | – |
| CVRX | Exit | CVRX INC | $0 | – | -275,000 | -100.0% | -0.10% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -1,881,300 | -100.0% | -0.12% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQ CORP 2 | $0 | – | -610,283 | -100.0% | -0.12% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -1,088,296 | -100.0% | -0.13% | – |
| Exit | ARYA SCIENCES ACQUISITN CORP | $0 | – | -1,000,000 | -100.0% | -0.20% | – | |
| IMRA | Exit | IMARA INC | $0 | – | -3,250,724 | -100.0% | -0.27% | – |
| SCPH | Exit | SCPHARMACEUTICALS INC | $0 | – | -1,856,904 | -100.0% | -0.27% | – |
| Exit | DA32 LIFE SCNCE | $0 | – | -1,500,000 | -100.0% | -0.30% | – | |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -958,980 | -100.0% | -1.07% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -3,984,681 | -100.0% | -1.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S | 33 | Q1 2023 | 25.5% |
| WAVE LIFE SCIENCES PTE LTD | 30 | Q1 2023 | 26.3% |
| TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
| ZOGENIX INC | 26 | Q4 2021 | 9.5% |
| BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
| DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
| RHYTHM PHARMACEUTICALS INC | 20 | Q1 2023 | 4.4% |
| ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
| KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 6.8% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | March 30, 2023 | 12,876,898 | 18.0% |
| Acrivon Therapeutics, Inc. | March 30, 2023 | 4,817,359 | 22.0% |
| GH Research PLC | March 30, 2023 | 5,561,118 | 10.7% |
| DICE Therapeutics, Inc. | March 29, 2023 | 7,660,615 | 16.1% |
| CureVac N.V. | March 27, 2023 | 12,245,955 | 5.5% |
| Orchard Therapeutics plc | March 20, 2023 | 18,564,300 | 10.0% |
| Enliven Therapeutics, Inc. | February 27, 2023 | 2,122,465 | 5.2% |
| Mineralys Therapeutics, Inc. | February 24, 2023 | 3,180,920 | 7.8% |
| 5:01 Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-06-02 |
| 4 | 2023-06-02 |
| SC 13D/A | 2023-05-30 |
| 4 | 2023-05-22 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-05-15 |
| SC 13G/A | 2023-05-15 |
| SC 13G/A | 2023-05-15 |
| SC 13D/A | 2023-04-18 |
| SC 13D/A | 2023-04-10 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.